T1	Pharmacological_substance 40 58	interferon alfa-2b
N1000 	Reference T1 MeSH:C554127	interferon alfa-2b
T3	Pharmacological_substance 63 74	gemfibrozil
N1001 	Reference T3 MeSH:D015248	gemfibrozil
T4	Disorder 93 111	malignant melanoma
N1 	Reference T4 UMLS:C0025202	malignant melanoma
T5	Disorder 149 183	high-risk stage II or III melanoma
N2 	Reference T5 UMLS:C0025202	high-risk stage II or III melanoma
T6	Pharmacological_substance 216 232	interferon (IFN)
T7	Pharmacological_substance 298 313	IFN alfa-2b use
T8	Disorder 362 382	hypertriglyceridemia
N3 	Reference T8 UMLS:C0020557	hypertriglyceridemia
T9	Pharmacological_substance 503 514	IFN alfa-2b
N1002 	Reference T9 MeSH:C554127	IFN alfa-2b
T10	Pharmacological_substance 519 530	gemfibrozil
N1003 	Reference T10 MeSH:D015248	gemfibrozil
T11	Disorder 549 567	malignant melanoma
N4 	Reference T11 UMLS:C0025202	malignant melanoma
T12	Disorder 733 751	stage III melanoma
N5 	Reference T12 UMLS:C0025202	stage III melanoma
T13	Disorder 922 938;944 952	gastrointestinal symptoms
N6 	Reference T13 UMLS:C0426576	gastrointestinal symptoms
T14	Disorder 1039 1057	malignant melanoma
N7 	Reference T14 UMLS:C0025202	malignant melanoma
T15	Pharmacological_substance 1059 1067	IFN alfa
N1004 	Reference T15 MeSH:D016898	IFN alfa
T22	Pharmacological_substance 1307 1310	IFN
N1005 	Reference T22 MeSH:D007372	IFN
T23	Disorder 1319 1339	hypertriglyceridemia
N8 	Reference T23 UMLS:C0020557	hypertriglyceridemia
T24	Pharmacological_substance 1341 1352	gemfibrozil
N1006 	Reference T24 MeSH:D015248	gemfibrozil
T28	Pharmacological_substance 1519 1527	IFN alfa
N1007 	Reference T28 MeSH:D016898	IFN alfa
T31	Pharmacological_substance 1677 1685	IFN alfa
N1008 	Reference T31 MeSH:D016898	IFN alfa
T32	Pharmacological_substance 1700 1711	gemfibrozil
N1009 	Reference T32 MeSH:D015248	gemfibrozil
T34	Pharmacological_substance 1761 1764	IFN
N1010 	Reference T34 MeSH:D007372	IFN
T35	Disorder 1773 1793	hypertriglyceridemia
N9 	Reference T35 UMLS:C0020557	hypertriglyceridemia
T37	Pharmacological_substance 1912 1915	IFN
N1011 	Reference T37 MeSH:D007372	IFN
T38	Pharmacological_substance 1920 1931	gemfibrozil
N1012 	Reference T38 MeSH:D015248	gemfibrozil
T43	Pharmacological_substance 2037 2045	IFN alfa
N1013 	Reference T43 MeSH:D016898	IFN alfa
T44	Pharmacological_substance 2060 2071	gemfibrozil
N1014 	Reference T44 MeSH:D015248	gemfibrozil
T46	Pharmacological_substance 2134 2137	IFN
N1015 	Reference T46 MeSH:D007372	IFN
T47	Disorder 2146 2166	hypertriglyceridemia
N10 	Reference T47 UMLS:C0020557	hypertriglyceridemia
T2	Pharmacological_substance 1528 1539	gemfibrozil
N1016 	Reference T2 MeSH:D015248	gemfibrozil
T19	Subject 78 87	a patient
T20	Speculation_cue 0 9	Potential
T21	Subject 135 143	patients
T26	Disorder 318 351	primarily constitutional symptoms
T39	Subject 534 543	a patient
T42	Speculation_cue 463 472	potential
T48	Subject 669 695	a 43-year-old male patient
T51	Disorder 774 784	metastasis
N11 	Reference T51 UMLS:C2939419	metastasis
T16	Pharmacological_substance 1105 1137	investigational melanoma vaccine
T17	Pharmacological_substance 1138 1157	melanoma theraccine
T53	Combination 1084 1095	combination
T58	Speculation_cue 1998 2006	possible
T62	Speculation_cue 1638 1646	possible
T66	Disorder 1417 1427	GI disease
N12 	Reference T66 UMLS:C0017178	GI disease
T67	Disorder 1399 1413;1420 1427	cardiovascular disease
N13 	Reference T67 UMLS:C0007222	cardiovascular disease
T69	Speculation_cue 1509 1518	potential
